心泰医疗(02291.HK) 公布,向控股股东乐普(300003.SZ) 收购上海民为生物技术54.2384%股权,藉以进入高增长代谢及心血管赛道,完善全周期疾病治疗战略布局,现金代价10.88亿人民币。上海民为生物技术聚焦心血管、内分泌、代谢疾病及其并发症领域,拥有GPCR激动剂筛选平台LAGMA、RAF超长效分子开发平台和Dual-siRNA开发平台。(de/d)(港股报价延迟最少十五分钟。...
Source Link心泰医疗(02291.HK) 公布,向控股股东乐普(300003.SZ) 收购上海民为生物技术54.2384%股权,藉以进入高增长代谢及心血管赛道,完善全周期疾病治疗战略布局,现金代价10.88亿人民币。上海民为生物技术聚焦心血管、内分泌、代谢疾病及其并发症领域,拥有GPCR激动剂筛选平台LAGMA、RAF超长效分子开发平台和Dual-siRNA开发平台。(de/d)(港股报价延迟最少十五分钟。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.